ObsEva Gives Up On IVF Drug As Phase III Study Fails
Confirmatory Trial Dashes Hopes Of Improved Ongoing Pregnancy Rate
Executive Summary
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.